These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38465661)

  • 1. Pre-treatment [
    Chen J; Zhao Y
    Hematology; 2024 Dec; 29(1):2325317. PubMed ID: 38465661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic and Prognostic Value of
    Chen X; Qiao WL; Song JH; Liu CC; Han L; Wu S; Zhao JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1044-1049. PubMed ID: 37551475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [
    Liang X; Yang C; Su M; Zou L
    Curr Med Res Opin; 2024 May; 40(5):803-811. PubMed ID: 38626218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using
    Hao B; Zhao L; Luo NN; Ruan D; Pang YZ; Guo W; Fu H; Guo XY; Luo ZM; Wu J; Chen HJ; Wu H; Sun L
    BMC Cancer; 2018 Nov; 18(1):1192. PubMed ID: 30497426
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.
    Abe Y; Kitadate A; Usui Y; Narita K; Kobayashi H; Miura D; Takeuchi M; Oʼuchi E; Oʼuchi T; Matsue K
    Clin Nucl Med; 2019 May; 44(5):e336-e341. PubMed ID: 30889000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre
    Doma A; Zevnik K; Studen A; Prevodnik VK; Gasljevic G; Novakovic BJ
    Radiol Oncol; 2024 Mar; 58(1):15-22. PubMed ID: 38378029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of
    Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
    Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT.
    Zhou Z; Chen C; Li X; Li Z; Zhang X; Chang Y; Lu L; Cui Y; Ma Y; Zhang M
    Ann Hematol; 2015 Jun; 94(6):963-7. PubMed ID: 25547320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Utility and prognostic value of PET/CT, bone marrow biopsy and aspirate for detection of bone marrow involvement in diffuse large B-cell lymphoma].
    Jiang XY; Zou DM; Zhang YQ; Wang Z; Zhang W; Zhou DB; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):663-667. PubMed ID: 36709151
    [No Abstract]   [Full Text] [Related]  

  • 17. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT-based bone-marrow assessment shows potential in replacing routine bone-marrow biopsy in part of patients newly diagnosed with extranodal natural killer/T-cell lymphoma.
    Wang Y; Xie L; Tian R; Deng Y; Zhang W; Zou L; Zhang H; Liu J; Zhao S; Ding W; Liu W; Jiang M
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2529-2539. PubMed ID: 31485768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of bone marrow (18)F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma].
    Zhang Y; Zhou J; Wang L; Li JY; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):885-890. PubMed ID: 33113633
    [No Abstract]   [Full Text] [Related]  

  • 20. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
    Kaddu-Mulindwa D; Altmann B; Held G; Angel S; Stilgenbauer S; Thurner L; Bewarder M; Schwier M; Pfreundschuh M; Löffler M; Menhart K; Grosse J; Ziepert M; Herrmann K; Dührsen U; Hüttmann A; Barbato F; Poeschel V; Hellwig D
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3550-3559. PubMed ID: 33928400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.